356 related articles for article (PubMed ID: 26398543)
1. Voriconazole: How to Use This Antifungal Agent and What to Expect.
Malani AN; Kerr LE; Kauffman CA
Semin Respir Crit Care Med; 2015 Oct; 36(5):786-95. PubMed ID: 26398543
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and clinical use of voriconazole.
Thompson GR; Lewis JS
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
[TBL] [Abstract][Full Text] [Related]
4. Optimizing antifungal choice and administration.
Andes D
Curr Med Res Opin; 2013 Apr; 29 Suppl 4():13-8. PubMed ID: 23621589
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of voriconazole: Over a decade of use.
Levine MT; Chandrasekar PH
Clin Transplant; 2016 Nov; 30(11):1377-1386. PubMed ID: 27581783
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole: a new triazole antifungal agent.
Johnson LB; Kauffman CA
Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
[TBL] [Abstract][Full Text] [Related]
10. Alopecia and nail changes associated with voriconazole therapy.
Malani AN; Kerr L; Obear J; Singal B; Kauffman CA
Clin Infect Dis; 2014 Aug; 59(3):e61-5. PubMed ID: 24855150
[TBL] [Abstract][Full Text] [Related]
11. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
Cecil JA; Wenzel RP
Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
[TBL] [Abstract][Full Text] [Related]
14. Update on azole antifungals.
Zonios DI; Bennett JE
Semin Respir Crit Care Med; 2008 Apr; 29(2):198-210. PubMed ID: 18366001
[TBL] [Abstract][Full Text] [Related]
15. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
Lecefel C; Eloy P; Chauvin B; Wyplosz B; Amilien V; Massias L; Taburet AM; Francois H; Furlan V
J Clin Pharm Ther; 2015 Feb; 40(1):119-20. PubMed ID: 25417855
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole-refractory invasive aspergillosis.
Park SY; Yoon JA; Kim SH
Korean J Intern Med; 2017 Sep; 32(5):805-812. PubMed ID: 28835093
[TBL] [Abstract][Full Text] [Related]
18. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Takagi S; Araoka H; Uchida N; Uchida Y; Kaji D; Ota H; Nishida A; Ishiwata K; Tsuji M; Yamamoto H; Ito T; Matsuno N; Yamamoto G; Asano-Mori Y; Hayashi M; Izutsu K; Masuoka K; Wake A; Makino S; Yoneyama A; Taniguchi S
Int J Hematol; 2014; 99(5):652-8. PubMed ID: 24664791
[TBL] [Abstract][Full Text] [Related]
19. Fungal infections.
Kauffman CA
Proc Am Thorac Soc; 2006; 3(1):35-40. PubMed ID: 16493149
[TBL] [Abstract][Full Text] [Related]
20. PharmGKB summary: voriconazole pathway, pharmacokinetics.
Barbarino JM; Owusu Obeng A; Klein TE; Altman RB
Pharmacogenet Genomics; 2017 May; 27(5):201-209. PubMed ID: 28277330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
